HEMISPHERX BIOPHARMA INC (HEB) Stock Overview
USA - NYSEARCA:HEB -
HEB Key Statistics, Chart & Performance
The current stock price of HEB is 1.8 null. In the past month the price decreased by -19.28%. In the past year, price decreased by -85.12%.
HEB Latest News, Press Relases and Analysis
About HEB
Company Profile
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
Company Info
HEMISPHERX BIOPHARMA INC
2117 SW HIGHWAY 484
OCALA FL 34473
CEO: Thomas K. Equels
Phone: 215-988-0080
HEMISPHERX BIOPHARMA INC / HEB FAQ
What does HEB do?
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
What is the current price of HEB stock?
The current stock price of HEB is 1.8 null. The price decreased by -0.55% in the last trading session.
Does HEMISPHERX BIOPHARMA INC pay dividends?
HEB does not pay a dividend.
What is the ChartMill technical and fundamental rating of HEB stock?
HEB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is HEMISPHERX BIOPHARMA INC worth?
HEMISPHERX BIOPHARMA INC (HEB) has a market capitalization of 4.40M null. This makes HEB a Nano Cap stock.
What is the ownership structure of HEMISPHERX BIOPHARMA INC (HEB)?
You can find the ownership structure of HEMISPHERX BIOPHARMA INC (HEB) on the Ownership tab.
HEB Technical Analysis
HEB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HEB. HEB has a bad profitability rating. Also its financial health evaluation is rather negative.
HEB Financial Highlights
Over the last trailing twelve months HEB reported a non-GAAP Earnings per Share(EPS) of -5.540000000000001. The EPS decreased by -2418.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -3284.04% | ||
| ROA | -73.02% | ||
| ROE | -153.97% | ||
| Debt/Equity | 0.37 |